Deficient mismatch repair in colorectal cancer: current perspectives on patient management and future directions

References

• Leggett B , WhitehallV. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology138(6), 2088–2100 (2010).
   PubMed Web of Science ®Google Scholar
• Peltomaki P , AaltonenLA, SistonenPet al. Genetic mapping of a locus predisposing to human colorectal cancer. Science260(5109), 810–812 (1993).
   PubMed Web of Science ®Google Scholar
• Fishel R , LescoeMK, RaoMRet al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell75(5), 1027–1038 (1993).
   PubMed Web of Science ®Google Scholar
• Leach FS , NicolaidesNC, PapadopoulosNet al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell75(6), 1215–1225 (1993).
   PubMed Web of Science ®Google Scholar
• Aaltonen LA , SalovaaraR, KristoPet al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N. Engl. J. Med.338(21), 1481–1487 (1998).
   PubMed Web of Science ®Google Scholar
• Young J , SimmsLA, BidenKGet al. Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am. J. Pathol.159(6), 2107–2116 (2001).
   PubMed Web of Science ®Google Scholar
• Bronner CE , BakerSM, MorrisonPTet al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature368(6468), 258–261 (1994).
   PubMed Web of Science ®Google Scholar
• Nicolaides NC , PapadopoulosN, LiuBet al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature371(6492), 75–80 (1994).
   PubMed Web of Science ®Google Scholar
• Akiyama Y , SatoH, YamadaTet al. Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res.57(18), 3920–3923 (1997).
   PubMed Web of Science ®Google Scholar
• Miyaki M , KonishiM, TanakaKet al. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat. Genet.17(3), 271–272 (1997).
   PubMed Web of Science ®Google Scholar
• Ligtenberg MJ , KuiperRP, ChanTLet al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat. Genet.41(1), 112–117 (2009).
   PubMed Web of Science ®Google Scholar
• Suter CM , MartinDI, WardRL. Germline epimutation of MLH1 in individuals with multiple cancers. Nat. Genet.36(5), 497–501 (2004).
   PubMed Web of Science ®Google Scholar
• Sheridan TB , FentonH, LewinMRet al. Sessile serrated adenomas with low- and high-grade dysplasia and early carcinomas: an immunohistochemical study of serrated lesions “caught in the act”. Am. J. Clin. Pathol.126(4), 564–571 (2006).
   PubMed Web of Science ®Google Scholar
• Goldstein NS . Small colonic microsatellite unstable adenocarcinomas and high-grade epithelial dysplasias in sessile serrated adenoma polypectomy specimens: a study of eight cases. Am. J. Clin. Pathol.125(1), 132–145 (2006).
   PubMed Web of Science ®Google Scholar
• Rajagopalan H , BardelliA, LengauerC, KinzlerKW, VogelsteinB, VelculescuVE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature418(6901), 934 (2002).
   PubMed Web of Science ®Google Scholar
• Mcgivern A , WynterCV, WhitehallVLet al. Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam. Cancer3(2), 101–107 (2004).
   PubMedGoogle Scholar
• Toyota M , AhujaN, Ohe-ToyotaM, HermanJG, BaylinSB, IssaJP. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA96(15), 8681–8686 (1999).
   PubMed Web of Science ®Google Scholar
• Bond CE , NancarrowDJ, WocknerLFet al. Microsatellite stable colorectal cancers stratified by the BRAF V600E mutation show distinct patterns of chromosomal instability. PLoS One9(3), e91739 (2014).
   PubMed Web of Science ®Google Scholar
• Bond CE , UmapathyA, RamsnesIet al. p53 mutation is common in microsatellite stable, BRAF mutant colorectal cancers. Int. J. Cancer130(7), 1567–1576 (2012).
   PubMed Web of Science ®Google Scholar
• Samowitz WS , SweeneyC, HerrickJet al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res.65(14), 6063–6069 (2005).
   PubMed Web of Science ®Google Scholar
• Bettington ML , WalkerNI, RostyCet al. A clinicopathological and molecular analysis of 200 traditional serrated adenomas. Mod. Pathol. doi:10.1038/modpathol.2014.122 (2014) ( Epub ahead of print).
   PubMedGoogle Scholar
• Whitehall VL , WynterCV, WalshMDet al. Morphological and molecular heterogeneity within nonmicrosatellite instability-high colorectal cancer. Cancer Res.62(21), 6011–6014 (2002).
   PubMed Web of Science ®Google Scholar
• Nosho K , IraharaN, ShimaKet al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One3(11), e3698 (2008).
   PubMed Web of Science ®Google Scholar
• Weisenberger DJ , SiegmundKD, CampanMet al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet.38(7), 787–793 (2006).
   PubMed Web of Science ®Google Scholar
• Hinoue T , WeisenbergerDJ, LangeCPet al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res.22(2), 271–282 (2012).
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas N . Comprehensive molecular characterization of human colon and rectal cancer. Nature487(7407), 330–337 (2012).
   PubMed Web of Science ®Google Scholar
• Fang M , OuJ, HutchinsonL, GreenMR. The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG island methylator phenotype. Mol. Cell55(6), 904–915 (2014).
   PubMed Web of Science ®Google Scholar
• Whitehall V , DumenilT, MckeoneDet al. Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype. Epigenetics9(11), 1454–1460 (2014).
   PubMed Web of Science ®Google Scholar
• Hearne CM , GhoshS, ToddJA. Microsatellites for linkage analysis of genetic traits. Trends Genet.8(8), 288–294 (1992).
   PubMed Web of Science ®Google Scholar
• Ripley LS . Frameshift mutation: determinants of specificity. Annu. Rev. Genet.24, 189–213 (1990).
   PubMed Web of Science ®Google Scholar
• Kunkel TA . Frameshift mutagenesis by eucaryotic DNA polymerases in vitro. J. Biol. Chem.261(29), 13581–13587 (1986).
   PubMed Web of Science ®Google Scholar
• Perucho M . Cancer of the microsatellite mutator phenotype. Biol. Chem.377(11), 675–684 (1996).
   PubMed Web of Science ®Google Scholar
• Boland CR , ThibodeauSN, HamiltonSRet al. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res.58(22), 5248–5257 (1998).
   PubMed Web of Science ®Google Scholar
• Markowitz S , WangJ, MyeroffLet al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science268(5215), 1336–1338 (1995).
   PubMed Web of Science ®Google Scholar
• Mori Y , YinJ, RashidAet al. Instabilotyping: comprehensive identification of frameshift mutations caused by coding region microsatellite instability. Cancer Res.61(16), 6046–6049 (2001).
   PubMed Web of Science ®Google Scholar
• Rampino N , YamamotoH, IonovYet al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science275(5302), 967–969 (1997).
   PubMed Web of Science ®Google Scholar
• Souza RF , AppelR, YinJet al. Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. Nat. Genet.14(3), 255–257 (1996).
   PubMed Web of Science ®Google Scholar
• Lindor NM , BurgartLJ, LeontovichOet al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J. Clin. Oncol.20(4), 1043–1048 (2002).
   PubMed Web of Science ®Google Scholar
• Giardiello FM , AllenJI, AxilbundJEet al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology147(2), 502–526 (2014).
   PubMed Web of Science ®Google Scholar
• Bacher JW , FlanaganLA, SmalleyRLet al. Development of a fluorescent multiplex assay for detection of MSI-High tumors. Dis. Markers20(4–5), 237–250 (2004).
   PubMed Web of Science ®Google Scholar
• Pinol V , CastellsA, AndreuMet al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA293(16), 1986–1994 (2005).
   PubMed Web of Science ®Google Scholar
• Whitehall VL , WalshMD, YoungJ, LeggettBA, JassJR. Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. Cancer Res.61(3), 827–830 (2001).
   PubMed Web of Science ®Google Scholar
• Hendriks YM , WagnerA, MorreauHet al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology127(1), 17–25 (2004).
   PubMed Web of Science ®Google Scholar
• Plaschke J , EngelC, KrugerSet al. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. J. Clin. Oncol.22(22), 4486–4494 (2004).
   PubMed Web of Science ®Google Scholar
• Wu Y , BerendsMJ, MensinkRGet al. Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations. Am. J. Hum. Genet.65(5), 1291–1298 (1999).
   PubMed Web of Science ®Google Scholar
• Berends MJ , WuY, SijmonsRHet al. Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am. J. Hum. Genet.70(1), 26–37 (2002).
   PubMed Web of Science ®Google Scholar
• Vilar E , MorkME, CuddyAet al. Role of microsatellite instability-low as a diagnostic biomarker of Lynch syndrome in colorectal cancer. Cancer Genet.207(10–12), 495–502 (2014).
   PubMed Web of Science ®Google Scholar
• Hampel H , FrankelWL, MartinEet al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J. Clin. Oncol.26(35), 5783–5788 (2008).
   PubMed Web of Science ®Google Scholar
• Ward RL , HicksS, HawkinsNJ. Population-based molecular screening for Lynch syndrome: implications for personalized medicine. J. Clin. Oncol.31(20), 2554–2562 (2013).
   PubMed Web of Science ®Google Scholar
• Moertel CG , FlemingTR, MacdonaldJSet al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med.322(6), 352–358 (1990).
   PubMed Web of Science ®Google Scholar
• Haller DG , CatalanoPJ, MacdonaldJSet al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J. Clin. Oncol.23(34), 8671–8678 (2005).
   PubMed Web of Science ®Google Scholar
• Andre T , BoniC, NavarroMet al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol.27(19), 3109–3116 (2009).
   PubMed Web of Science ®Google Scholar
• Taieb J , TaberneroJ, MiniEet al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol.15(8), 862–873 (2014).
   PubMed Web of Science ®Google Scholar
• Allegra CJ , YothersG, O'ConnellMJet al. Bevacizumab in stage II–III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J. Clin. Oncol.31(3), 359–364 (2013).
   PubMed Web of Science ®Google Scholar
• Sauer R , LierschT, MerkelSet al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J. Clin. Oncol.30(16), 1926–1933 (2012).
   PubMed Web of Science ®Google Scholar
• Nordlinger B , SorbyeH, GlimeliusBet al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol.14(12), 1208–1215 (2013).
   PubMed Web of Science ®Google Scholar
• Heinemann V , Von WeikersthalLF, DeckerTet al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol.15(10), 1065–1075 (2014).
   PubMed Web of Science ®Google Scholar
• Price TJ , SegelovE, BurgeMet al. Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. Expert Rev. Anticancer Ther.14(12), 1477–1493 (2014).
   PubMed Web of Science ®Google Scholar
• Douillard JY , OlinerKS, SienaSet al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med.369(11), 1023–1034 (2013).
   PubMed Web of Science ®Google Scholar
• Thibodeau SN , BrenG, SchaidD. Microsatellite instability in cancer of the proximal colon. Science260(5109), 816–819 (1993).
   PubMed Web of Science ®Google Scholar
• Sargent DJ , MarsoniS, MongesGet al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol.28(20), 3219–3226 (2010).
   PubMed Web of Science ®Google Scholar
• Martin CM , GuzmanEC. DNA replication initiation as a key element in thymineless death. DNA Repair (Amst.)10(1), 94–101 (2011).
   PubMed Web of Science ®Google Scholar
• Zhang H , RichardsB, WilsonTet al. Apoptosis induced by overexpression of hMSH2 or hMLH1. Cancer Res.59(13), 3021–3027 (1999).
   PubMed Web of Science ®Google Scholar
• Gryfe R , KimH, HsiehETet al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N. Engl. J. Med.342(2), 69–77 (2000).
   PubMed Web of Science ®Google Scholar
• Sinicrope FA , FosterNR, ThibodeauSNet al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J. Natl Cancer Inst.103(11), 863–875 (2011).
   PubMedGoogle Scholar
• Wright CM , DentOF, BarkerMet al. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br. J. Surg.87(9), 1197–1202 (2000).
   PubMed Web of Science ®Google Scholar
• Jernvall P , MakinenMJ, KarttunenTJ, MakelaJ, VihkoP. Microsatellite instability: impact on cancer progression in proximal and distal colorectal cancers. Eur. J. Cancer35(2), 197–201 (1999).
   PubMedGoogle Scholar
• Kim GP , ColangeloLH, WieandHSet al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute–National Surgical Adjuvant Breast and Bowel Project collaborative study. J. Clin. Oncol.25(7), 767–772 (2007).
   PubMed Web of Science ®Google Scholar
• Westra JL , SchaapveldM, HollemaHet al. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J. Clin. Oncol.23(24), 5635–5643 (2005).
   PubMed Web of Science ®Google Scholar
• Hutchins G , SouthwardK, HandleyKet al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J. Clin. Oncol.29(10), 1261–1270 (2011).
   PubMed Web of Science ®Google Scholar
• Sargent DJ , ShiQ, YothersGet al. Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): a pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database. J. Clin. Oncol.32(5s), Abstract 3507 (2014).
   Google Scholar
• Roth AD , DelorenziM, TejparSet al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J. Natl Cancer Inst.104(21), 1635–1646 (2012).
   PubMedGoogle Scholar
• Bertagnolli MM , RedstonM, ComptonCCet al. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer – a study of CALGB 9581 and 89803. J. Clin. Oncol.29(23), 3153–3162 (2011).
   PubMed Web of Science ®Google Scholar
• Sinicrope FA , MahoneyMR, SmyrkTCet al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J. Clin. Oncol.31(29), 3664–3672 (2013).
   PubMed Web of Science ®Google Scholar
• Gavin PG , ColangeloLH, FumagalliDet al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin. Cancer Res.18(23), 6531–6541 (2012).
   PubMed Web of Science ®Google Scholar
• Flejou JF , AndreT, ChibaudelBet al. Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study. J. Clin. Oncol.31, Abstract 3524 (2013).
   Web of Science ®Google Scholar
• Tournigand C , AndreT, BonnetainFet al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant treatment of colon cancer trial. J. Clin. Oncol.30(27), 3353–3360 (2012).
   PubMed Web of Science ®Google Scholar
• Popat S , HubnerR, HoulstonRS. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol.23(3), 609–618 (2005).
   PubMed Web of Science ®Google Scholar
• Ribic CM , SargentDJ, MooreMJet al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med.349(3), 247–257 (2003).
   PubMed Web of Science ®Google Scholar
• Bertagnolli MM , NiedzwieckiD, ComptonCCet al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J. Clin. Oncol.27(11), 1814–1821 (2009).
   PubMed Web of Science ®Google Scholar
• Sinicrope FA , SmyrkTC, TougeronDet al. Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas. Cancer119(15), 2765–2770 (2013).
   PubMed Web of Science ®Google Scholar
• Labianca R , NordlingerB, BerettaGDet al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.24(Suppl. 6), vi64–vi72 (2013).
   PubMed Web of Science ®Google Scholar
• Papamichael D , AudisioRA, GlimeliusBet al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann. Oncol. pii: mdu253 (2014) ( Epub ahead of print).
   PubMedGoogle Scholar
• Tran B , KopetzS, TieJet al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer117(20), 4623–4632 (2011).
   PubMed Web of Science ®Google Scholar
• Goldstein J , TranB, EnsorJet al. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann. Oncol.25(5), 1032–1038 (2014).
   PubMed Web of Science ®Google Scholar
• Venderbosch S , NagtegaalID, MaughanTSet al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin. Cancer Res.20(20), 5322–5330 (2014).
   PubMed Web of Science ®Google Scholar
• Des Guetz G , UzzanB, NicolasP, SchischmanoffO, PerretGY, MorereJF. Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis. Anticancer Res.29(5), 1615–1620 (2009).
   PubMed Web of Science ®Google Scholar
• Loupakis F , CremoliniC, LonardiSet al. Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study. J. Clin. Oncol.32(5s), Abstract 3519 (2014).
   Google Scholar
• Liu L , ShiH, BleamMRet al. Antitumor effects of dabrafenib, trametinib, and panitumumab as single agents and in combination in BRAF-mutant colorectal carcinoma (CRC) models. J. Clin. Oncol.32(5s), Abstract 3513 (2014).
   Google Scholar
• Van Geel R , ElezE, BendellJCet al. Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the a-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer. J. Clin. Oncol.32(5s), Abstract 3514 (2014).
   Google Scholar
• Van Cutsem E , KohneCH, LangIet al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol.29(15), 2011–2019 (2011).
   PubMed Web of Science ®Google Scholar
• Di Nicolantonio F , MartiniM, MolinariFet al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol.26(35), 5705–5712 (2008).
   PubMed Web of Science ®Google Scholar
• Dienstmann R , GuinneyJ, DelorenziMet al. Coloretcal Cancer Subtyping Consortium (CRCSC) identification of a consnesus of molecular subtypes. J. Clin. Oncol.32(5s), Abstract 3511 (2014).
   Google Scholar
• Mclornan DP , ListA, MuftiGJ. Applying synthetic lethality for the selective targeting of cancer. N. Engl. J. Med.371(18), 1725–1735 (2014).
   PubMed Web of Science ®Google Scholar
• Venderbosch S , NagtegaalID, MaughanTSet al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin. Cancer Res.20(20), 5322–5330 (2014).
   PubMed Web of Science ®Google Scholar